Oropfen (Flurbiprofen)

Flurbiprofen blocks cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, reducing the synthesis of prostaglandins that mediate inflammation, pain, and fever. Lower prostaglandin levels lead to decreased swelling and discomfort at the affected site.

The dosage of Oropfen is determined by the prescribing clinician based on the patient’s condition, age, renal and hepatic function, and any concomitant therapies. The prescriber sets the appropriate strength and frequency.

Flurbiprofen is generally avoided during the third trimester of pregnancy because of potential fetal cardiovascular effects, and it is not recommended for breastfeeding mothers unless the benefit outweighs the risk. Consultation with a healthcare provider is essential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Flurbiprofen has a relatively rapid onset of analgesia and potency comparable to ibuprofen, but its COX‑1 inhibition may confer a higher risk of gastrointestinal side effects than more COX‑2 selective agents such as celecoxib. Choice depends on efficacy, safety profile and patient factors.

Store Oropfen at room temperature, below 25 °C, in the original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children.

Oropfen is supplied as oral tablets that are taken by mouth with a full glass of water. It may be taken with or without food, although taking it with meals can reduce gastrointestinal discomfort.

The most serious adverse events include gastrointestinal ulceration or bleeding, severe renal impairment, hepatotoxicity, and rare hypersensitivity reactions such as Stevens‑Johnson syndrome or anaphylaxis. Patients should seek immediate medical attention if they experience signs of these conditions.

Oropfen should be avoided in individuals with known hypersensitivity to flurbiprofen or other NSAIDs, active peptic ulcer disease, severe heart failure, uncontrolled hypertension, third‑trimester pregnancy, and in patients with significant renal or hepatic impairment unless specifically directed by a physician.